pharmaceutical-sciences-2019-scientifictracks

7 / 11

allied
academies
Page 25
July 05-06, 2019 | Paris, France
Pharmaceutics and Advanced Drug Delivery Systems
2nd International Conference and Exhibition on
Asian Journal of Biomedical and Pharmaceutical Sciences | ISSN:2249-622X | Volume 9
Dual loaded actively targeted liposomes for anti-resistance treatment of melanoma
Harshita Mishra1, Sushama Talegaonkar1,2, Zeenat Iqbal1 and Manu Jaggi3
1 Jamia Hamdard University, India
2 Delhi Pharmaceutical Sciences and Research University, India
3 Dabur Research Foundation, India
Melanoma is one of the deadliest cancers with very
low response and survival rates. Main reason of poor
outcomes of therapy is the inherent resistance of melanoma
cells.Survivinisaproteinwhichisoverexpressedbymelanoma
cells and is known to impart resistance to them against
apoptosis which is supposed to be induced by chemotherapy.
Eugenol has been reported to inhibit survivin in breast cancer
cells. Thus, in order to fight resistant melanoma in a more
efficient manner, we formulated hyaluronic acid (HA) coated
liposomes loaded with eugenol along with dacrabazine
which is the gold standard chemotherapeutic agent used for
melanoma treatment. After synthesizing the liposomes using
solvent injection method, QbD was applied to optimize and
obtain a final formulation with desired quality attributes. The
optimized formulation was then subjected to performance
analysis in cell lines and animals. Coated-Dacarbazine Eugenol
Liposomes were found to possess almost 9 folds more
cytotoxicity than dacarbazine solution against melanoma cell
lines (at dacarbazine concentration of 0.5 µg/ml). The number
of late apoptotic cells was also found to be much higher
in formulation treated cells in comparison to dacarbazine
solution treated cells. Migration assay and proliferation study
also indicated towards considerably greater inhibition of cell
migration and proliferation by Coated-Dacarbazine Eugenol
Liposomes, signifying its potential against metastasis. Results
of pharmacodynamic study on melanoma bearing C57BL/6
mice revealed that our formulation could significantly delay
the tumor growth in comparison to dacarbazine solution; and
biodistribution study confirmed the long circulating nature of
theformulation.Thus,theresultsofthisstudyindicatetowards
better possibilities of melanoma treatment if the treatment is
focusedonspecificresistancemechanismofthisdeadlycancer.
Speaker Biography
Harshita Mishra is about to finish her doctorate in Pharmaceutics from
Jamia Hamdard University, India. She has 14 international publications
and around 300 citations. She has also written 5 book chapters in
books edited by Elsevier, Stanford etc. Her educational background
includes Bachelor of Pharmacy, Master of Pharmacy and Post Graduate
Diploma in Intellectual Property Rights. She is a two times qualifier of
GPAT which is an all India level aptitude and evaluation exam. She has
twice received Elsevier’s ‘Top 25 Hottest Articles’ award for her paper
on metal nanoparticles. She has presented papers in 7 International
and National Conferences and won awards in 3 of them. Her areas of
interest include Nanotechnology and Cancer treatment.
e:
Notes:
Harshita Mishra et al., Asian J Biomed Pharmaceut Sci, | ISSN: 2249-622X
Volume 9